# OnCo record paper-xm22-03-bondarenko-bmc-cancer-2013 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-xm22-03-bondarenko-bmc-cancer-2013" ;
  schema:name "Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)"@en ;
  schema:description "In women having chemotherapy for breast cancer, a single dose of the new white-cell booster lipegfilgrastim kept the dangerous dip in white cells as short as the standard booster pegfilgrastim, with no cases of infection-related fever on the new drug."@en ;
  schema:url <https://onco.cc/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1186/1471-2407-13-386>, <https://pubmed.ncbi.nlm.nih.gov/23945072/>, <https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex> ;
  schema:sameAs <https://doi.org/10.1186/1471-2407-13-386> ;
  schema:datePublished "2013"^^xsd:gYear ;
  schema:author "Bondarenko I, Gladkov OA, Elsaesser R, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/lipegfilgrastim/>, <https://onco.cc/drugs/pegfilgrastim/> ;
  onco:companies <https://onco.cc/companies/teva/> ;
  onco:trials <https://onco.cc/trials/xm22-03/> ;
  onco:journals <https://onco.cc/journals/bmc-cancer/> .